Repositive is preparing to host its Pre-Clinical Oncology Showcase for EORTC-NCI-AACR 2018 at the Dublin Convention Centre on Wednesday 14 November from 7pm. The Showcase is open to all involved in pre-clinical oncology research and will feature representatives from three key Contract Research Organisations (CROs) – Mark Treherne, Chief Executive of Cellesce, Leo Price, CEO of OcellO and Jens Hoffman, CEO of EPO Berlin. The speakers will discuss their companies’ cutting-edge 3D organoid technologies, followed by an audience debate on how these innovations could change cancer research and drug development.
In addition to providing a platform to explore how new developments will disrupt the oncology and immuno-oncology fields, the Showcase will support Repositive’s growing Translational Oncology Network. The Translational Oncology Network is a pre-competitive community that Repositive is building to enable pre-clinical cancer researchers to discover the latest technologies, discuss the toughest issues facing the field and connect with peers across the globe.
Repositive CEO and Founder, Fiona Nielsen, explained: “Since Repositive was founded in 2014 we have made enormous strides towards removing the barriers that researchers face in accessing essential data, products and services, by enabling secure sharing and discovery through the development and roll-out of our platform. Our Cancer Models product, which is built on our platform, is already well on track to become the largest global online resource for cancer models. However, to drive drug discovery further and faster, we must nurture relationships that facilitate the exchange of critical knowledge and best practice across the industry.
“It is really important that we invest in building the community of researchers too, through our Translational Oncology Network, and we hope to see many individuals involved in pre-clinical oncology research at the Showcase in Dublin. We want to hear how we can provide more support for researchers – for the ultimate benefit of patients and their families who are waiting for better treatments and cures.”
Mark Treherne, Chief Executive of Cellesce, said: “Cellesce are very much looking forward to presenting at this Repositive event. We see considerable benefits in making our organoid mutation data available in partnership with Repositive and making our organoids more widely available to the cancer research community.”
Repositive will be based at Booth B6 in the Exhibit Hall for the duration of EORTC-NCI-AACR 2018, and, while the Pre-Clinical Oncology Showcase is free to attend, advance registration is recommended. The Showcase is not affiliated with EORTC-NCI-AACR 2018 and is open to anyone involved in pre-clinical oncology research.